You are about to leave the Clinical Value website now.
PIVKA-II has been extensively studied as a biomarker in HCC. However, its diagnostic capability varies across HCC studies. This study aimed to compare the performance of PIVKA-II with AFP in the diagnosis of HCC.
Xing H, Zheng YJ, Han J, Zhang H, Li ZL, Lau WY, Shen F, Yang T…
This study aims to determine the clinical value of serum Prothrombin induced by vitamin K absence-II (PIVKA-II) in early hepatocellular carcinoma (HCC), and to explore its relationship with vascular invasion and HBV DNA.
Wu J, Xiang Z, Bai L, He L, Tan L, Hu M, Ren Y…
In this video, Dr Bao Toan Nguyen from MEDIC-LAB Ho Chi Minh discusses how PIVKA-II can complement AFP in assisting clinicians in the early detection and overall management of HCC, and his experience with PIVKA-II at MEDIC-LAB. …
This presentation has 2 parts. In the first part of this presentation, Prof. Nobuharu Tamaki discusses the diagnostic utility of PIVKA-II in HCC, and the potential etiologies where PIVKA-II may be useful in surveillance and detection of HCC. In the second half, he discusses the correlation between PIVKA-II levels and treatment outcomes, and how PIVKA-II can potentially be used for treatment monitoring in HCC….
Detection of HCC at early stages remains a challenge, with less than 20% of patients being diagnosed at an early stage, when they can benefit from potentially curative therapies(1). In this presentation, Prof. Tawesak Tanwandee discusses the role of tumour markers for early diagnosis of HCC, as well as prognosis and response to treatment. …
In this presentation, Prof. Ming Lung Yu discusses the results of his study, which aims to address the diagnostic accuracy of HCC using Elecsys GAAD algorithmic score as compared to AFP and PIVKA-II, with or without the complementation of sonography. …